





Methylation profiling report

,

Sample identifier: sampleName1540574235

Sentrix ID: 202273260157_R07C01

Material type: KRYO DNA

Gender: NA

Supplier diagnosis: -

Supplier information

Automatic prediction	
Array type:	EPIC
Material type:	KRYO DNA
Gender:	male
Legend: ✔ OK Supplier information or prediction not available	★Warning, missmatch of prediction and supplier information

Brain tumor methylation classifier results (v11b4)


Methylation classes (MCs with score >= 0.3)	Calibrated score	Interpretation	n
methylation class family Glioblastoma, IDH wildtype	0.97	match	~
MC family members with score >= 0.1			
methylation class glioblastoma, IDH wildtype, subclass RTK I	0.93	match	•
Legend: ✓ Match (score >= 0.9) X No match (score < 0.9): possibly still relevant for low tumor content ar quality cases.	d low DNA • Match to (score >=	MC family meml : 0.5)	oer

Class descriptions

Methylation class family Glioblastoma, IDH wildtype: The methylation class family "Glioblastoma, IDH wildtype" comprises the methylation classes glioblastoma, IDH wildtype, subtype RTK I to III, glioblastoma, IDH wildtype, subtype mesenchymal, glioblastoma, IDH wildtype, subtype MYCN and glioblastoma, IDH wildtype, subtype midline.

Methylation class glioblastoma, IDH wildtype, subclass RTK I: The methylation class "glioblastoma, IDH wildtype, subclass RTK I" is comprised of tumors with a histological diagnosis of glioblastoma, IDH wildtype. The tumors are located in the cerebral hemispheres. Median age is 64 years (range 29 to 84). Recurrent chromosomal alterations are gain of chromosome 7 with or without EGFR amplification (>80%), loss of 9p21 (CDKN2A/B; >50%) and chromosome 10 loss (>70%). Amplifications of the PDGFRA oncogene are enriched in this class (present in 20-30% of cases). Expression profiles often resemble the 'Proneural' subgroup according to the TCGA classification.


Copy number variation profile



Depiction of chromosome 1 to 22 (and X/Y if automatic prediction was successful). Gains/amplifications represent positive, losses negative deviations from the baseline. 29 brain tumor relevant gene regions are highlighted for easier assessment. (see Hovestadt & Zapatka, http://www.bioconductor.org/packages/devel/bioc/html/conumee.html)

MGMT promotor methylation (MGMT-STP27)

MGMT promotor status prediction



(see Bady et al, J Mol Diagn 2016; 18(3):350-61)

Disclaimer

Classification using methylation profiling is a research tool under development, it is not verified and has not been clinically validated. Implementation of the results in a clinical setting is in the sole responsibility of the treating physician. Intended for non-commercial use only.

Run information

Report: idat_reportBrain_v11b4_sample Version 2.0 Task version:

Task	Version
idat_qc	2.0
idat_predictBrain	2.1
idat_rs_gender	2.0
idat_predictMGMT	2.0
idat_cnvp	3.0
idat_reportBrain_v11b4	2.0